Marin B-M, Porath KA, Jain S, Kim M, Conage-Pough JE, Oh J-H, Miller CL, Talele S, Kitange GJ, Tian S et al..  2021.  Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.. Neuro Oncol. 23(12):2042-2053.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK et al..  2018.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 20(2):184-191.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.  2018.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.. Drug Metab Dispos. 46(5):658-666.

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.  2017.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res. 123:10-25.